Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors

Erfan, GamzePuig, SusanaCarrera, CristinaArance, AnaGaba, LydiaVictoria, IvanMalvehy, Josep2022-05-112022-05-1120170001-55551651-2057https://doi.org/10.2340/00015555-2488https://hdl.handle.net/20.500.11776/8658[No Abstract Available]en10.2340/00015555-2488info:eu-repo/semantics/openAccessMetastatic MelanomaVemurafenibMutationsDabrafenibSurvivalDevelopment of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK InhibitorsEditorial972258260Q1WOS:0003938955000172-s2.0-8501200896427353949Q1